HR 653 & S 305 National Childhood Brain Tumor Prevention Network Act of 2009 Lloyd Morgan, Brain Tumor Survivor Dr. Tarik Tihan, Pediatric.

Slides:



Advertisements
Similar presentations
Cell phones and brain cancer: Unlocking the controversy? Faina Linkov, PhD Assistant Professor, University of Pittsburgh Cancer Institute.
Advertisements

Research Protocol ACRIN 6678 Learning About PET/CT Scans: Can PET/CT scans provide helpful information for the treatment of non-small cell lung cancer?
Pancreas Cancer Nimisha K. Parekh, MD, MPH
From X-rays to Cordless Phones: Radiation Causes Brain Tumors Lloyd Morgan.
Clinical Trials Hanyan Yang
Purposes and uses of cancer registration E.E.U. Akang Department of Pathology University College Hospital Ibadan, Nigeria.
Childhood Cancer Gabby Kulikowski & Kellie Campbell.
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
BRAIN TUMOR. What is it?  Brain neoplasms are a diverse group of primary (nonmetastatic) tumors arising from one of the many different cell types within.
How are cancer statistics kept up to date?.  Example:  Dx stage II colon cancer  Cancer has metastasized to the liver – 2009  How does the.
By Denae Bush.   1.The disease caused by an uncontrolled division of abnormal cells in a part of the body.  2.A malignant growth or tumor resulting.
Basics of Pediatric Oncology Margret E. Merino, MD Pediatric Hematology/Oncology WRAMC.
Introduction to Molecular Epidemiology Jan Dorman, PhD University of Pittsburgh School of Nursing
Biology in Focus, HSC Course Glenda Childrawi, Margaret Robson and Stephanie Hollis A Search For Better Health Topic 11: Epidemiology.
Dr H.Niroomand M.D. Aja University Of Medical Sience Epidemiology & Etiology.
Long term use Mobile Phone and Brain Tumor Risk Presented to Prof. Dr. Eduard Heindl By Swapna Nelli.
Genetic Alterations of TP53 Gene in Brain Astrocytic Tumours Methodology Θ Eighty-three brain tumor biopsies were collected and used in this study. Thirty.
Multiple Choice Questions for discussion. Part 2
Another way to think of cancer is “Mitosis Run Amok.”
NCI’s Division of Cancer Epidemiology and Genetics
1 Targeted Strategies to Improve Physician and Patient Access to Cancer Clinical Research An Overview of Coalition Programs and Services Ruth Lambersky.
Epidemiology The Basics Only… Adapted with permission from a class presentation developed by Dr. Charles Lynch – University of Iowa, Iowa City.
 2011 Johns Hopkins Bloomberg School of Public Health Jonathan M. Samet, MD, MS Director, USC Institute for Global Health Professor and Flora L. Thornton.
COMPONENTS OF A GOOD GRANT PROPOSAL Philip T. LoVerde.
 Cancer is a group of more than 100 diseases that develop over time › Involve the uncontrolled division of the body’s cells  Cancer is the 2 nd leading.
Group Number: 2 Britney Porter, Sandra Nguyen, Eduardo Vargas and Samender Singh Randhawa.
Ostoesarcoma By: Tori Hagel. Osteosarcoma  A malignant tumor of bone in which there is a proliferation of osteoblast.  A type of bone cancer.
10/16/2015C.R. Apap1 Lung cancer: a preventable disease Epidemiology addresses issues related to   Heredity,  Life-style, and  Environment.
CISNET and BCSC: Working Together To Model The Population Impact Breast Cancer Screening A Celebration of the Work of the Breast Cancer Surveillance Consortium.
California Stroke Registry Right Care Initiative Meeting August 13, 2012.
Brain Tumor Risk Factors
A short introduction to epidemiology Chapter 2b: Conducting a case- control study Neil Pearce Centre for Public Health Research Massey University Wellington,
Case-control study Chihaya Koriyama August 17 (Lecture 1)
Measures of Association Intermediate Epidemiology.
Associated Web sites CustomizableMaps The Atlas On-Line.
Genes and the Environment in Cancer Causation Joseph F. Fraumeni, Jr., M.D. National Cancer Institute January 9, 2007 Third Annual Alan S. Rabson Award.
First Author: Radu Cristina Co-Authors: Stefan Anda Tripon Florin Crauciuc George Coordinators: Banescu Claudia, MD Demian Smaranda, MD The importance.
INTRODUCTION TO PEDIATRIC ONCOLOGY Prof.Dr.Reha Cengizlier
Initiating phase 1 clinical trials in pediatric oncology National Cancer Institute Perspective Barry Anderson, MD, PhD Pediatric Section Cancer Therapy.
National Cancer Intelligence Network data usage 17 November 2015 – Veronique Poirier – Principal Cancer Analyst – NCIN.
ACS CAN 2015 Legislative Update Jen Schulte American Cancer Society Cancer Action Network.
Enrollment and Monitoring Procedures for NCI Supported Clinical Trials Barry Anderson, MD, PhD Cancer Therapy Evaluation Program National Cancer Institute.
AAPM&R Annual Assembly Boston, Massachusetts NIH - Promoting a Robust Pain, Musculoskeletal, and Rehabilitation Research Portfolio Jennifer Zumsteg, M.D.
Cancers of the Digestive System November 19, 2007 NCDD Meeting Chair: John M. Carethers, MD Vice Chair: Robert Sandler, MD, MPH.
C-1 Pegfilgrastim (Neulasta  ) Oncologic Drugs Advisory Committee Pediatric Subcommittee October 20, 2005 Amgen Inc.
+ Child & Adolescent Psychology Welcome to Seminar #9.
Cancer =Uncontrolled cell growth due to gene mutations -Cancer is always genetic, but it is not necessarily inherited.
Dr Heather O Dickinson My web page Department of Child Health University of Newcastle My web page Audit of cancer registrations notified by National Health.
Full Proposal for the German Cancer Aid Priority Program 'Translational Oncology' (2st call) 2015 Lead Applicants: Prof. Dr. med. Magnus von Knebel Doeberitz.
Bladder cancer! By Shamier Daniels. it is a disease in which abnormal cells multiply...
SNDA # GLIADEL® WAFER (Polifeprosan 20 with Carmustine Implant) APPLICANT: GUILFORD PHARMACEUTICALS ODAC: December 6, 2001 Medical Reviewer: Alla.
Brain Tumors Mark Browning, M.D. IUSME. Differential Diagnosis includes: Primary CNS tumor Most common primary sites of brain mets: – Lung – Breast.
Cancer The biological formation of cancer and treatments for the disease.
Cell Biology & Cancer Unit Objective 1 Cancer types, incidence, pre-disposition, and risk factors Biomedical Technology.
Next generation genomics: translation into clinically useful applications in health care Prof.dr. Martina Cornel
Northern Virginia National Society of Black Engineers Jr. Chapter Bio-Medical Competitio n.
Tissue Collection & Banking Facility
Brain Tumor Epidemiology Consortium (BTEC)
Developing a Comprehensive Site Selection Process for a Cancer Network in a Resource-Limited Settings in Sub-Saharan Africa Meg Wirth AMC Operations &
Sarah Leary, MD MS CBTTC 5/25/2016
Li-Fraumeni Syndrome Wendy Kohlmann, MS, CGC
Ionizing Radiation Exposures are from X-rays, A-bombs, radioactivity
Ionizing Radiation Exposures are from X-rays, A-bombs, radioactivity
Northwest Tribal Epidemiology Center
Protocol Summary National Wilms Tumor Study Group (NWTS)
Effect of Obesity on Prognosis after Early Breast Cancer
Introduction to Epidemiology
1. The rising incidence of testicular cancer among young men in Canada
Presentation transcript:

HR 653 & S 305 National Childhood Brain Tumor Prevention Network Act of 2009 Lloyd Morgan, Brain Tumor Survivor Dr. Tarik Tihan, Pediatric Neuro-pathologist

2 Why Is This Bill Needed? Almost nothing is known about the causes of Childhood Brain Tumor (CBT) No single institutions can possibly do a CBT study on their own There has never been a comprehensive investigation into the cause of CBT IF WE DON’T LOOK, WE WILL NEVER KNOW

3 Childhood Brain Tumor Facts Leading cause of death from solid tumors in US children 1 st most common form of solid tumor in US children 2 nd most common malignancy among US children Still considered an orphan disease

4 CBT is an Orphan Disease with a costly profile Surgery only (30%)$136,531 per child Surgery & Radiation (30%)$216,531 per child Surgery, Radiation & Chemotherapy (40%) $296,367 per child AVERAGE COST$ 224,429 per child Cost of Initial Treatment per child; calculated for the first line of treatment options. Source :California Childhood Brain Tumor Consortium Study. Dr. Paul Fisher, Stanford University, 2006

5 CBT results in loss of many years of potential life Source :Average years of Potential Life Lost for Childhood Brain Tumors. Thuppal et al. Neuroepidemiology. 2006;27(1):22-7.

6 The incidence of the most common childhood glioma is increasing. Childhood (0-19 yr) Age Adjusted Incidence Rates for Pilocytic Astrocytoma

7 There are numerous types of CBTs and some have been recently defined Newly Described Tumor Types by WHO (2007) Angiocentric Glioma Pilomyxoid Astrocytoma Papillary Glioneuronal Tumor Rosette-forming Glioneuronal Tumor of the 4 th Ventricle (RGNT) Papillary Tumor of the Pineal Region Pituicytoma Spindle Cell Oncocytoma

8 Causes of Childhood Brain Tumors Therapeutic X-ray to the head <2% A small fraction of all childhood tumors. Genetic diseases <5% Tumor predisposition syndromes such as neurofibromatosis, tuberous sclerosis, nevoid basal cell carcinoma syndrome, Turcot syndrome, Li-Fraumeni syndrome <5% of childhood brain tumors UNKNOWN >90% IF WE DON’T LOOK, WE CANNOT LEARN

9 The current research process Each study is a piece of a 5,000 piece jig-saw puzzle 32 studies of childhood ependymomas funded 32 pieces of the puzzle ,444 children No common protocol What does the jig-saw picture look like? Impossible to see the picture

10 Challenges to Studies on Causes and Risk Factors for Childhood Brain Tumors Insufficient number of children to study risk factors The causes/risk factors are likely to be multiple with complex interactions Without common protocol results cannot be combined Example: 32 studies of ependymomas Number of children in studies Minimum= 11 children ;maximum=92 children No study use same protocol Single factor studied: prognostic factor 32 studies; little to nothing learned!

11 32 Studies: What Is The Picture?

12 The Rationale Childhood Brain Tumor (CBT) is an Orphan Disease with a costly profile. The incidence of the most common type of CBT is increasing There are new histological types of CBT in the new WHO 2007 No single institution can accrue sufficient number of “similar” CBT patients in a reasonable period Causal associations are not likely to be direct All aspects of CBT needs to be studied together Genetics, epigenetics, environment, nutrition, pathology, viruses, and clinical

13 Study Design-National Consortium Regions with sufficient patient population for epidemiological study Study the “whole picture” rather than one part at a time All relevant disciplines (multiple experts/resources ) Environmental exposure analysis (Is there an environmental cause?) Nutritional analysis (Is there something in the diet?) Genetic/Genomic analysis (What role do genes play?) Epigenetic analysis (What turns genes on or off?) Pathological evaluation/archival information (Are CBT types changing?) Guthrie cards/perinatal information (Has the child’s DNA mutated since birth?) Correlation with clinical treatment groups (What are prognostic factors and which treatment can address the causative events?)

14 CBT Study Plan Case-Control design (1:2 or greater ratio) Regional Consortia: possibly 5 (>2,500 children) California/Northwest Texas/Southwest Midwest Florida/Southeast New York/Northeast Same procedures and analyses Designated Central Laboratories for specialized testing Central Data Repository to collect all research data Available to all researchers whether or not a study investigator Provisions for consensus reporting

15 Study Coordination Funding is additional money to NIH budget Consortia and study coordination by NCI Awards grants to regional consortium Coordinates consortia Coordinates central statistics and data management Existing NIH Research Priority Plan and support a multicenter case-control study of the etiology of childhood brain cancer through the Brain Tumor Epidemiology Consortium (BTEC) NIH Research Plan for Children’s Brain Tumors, 2008

Legislative Strategy for House and Senate Based on prior experience in passing the Benign Brain Tumor Cancer Registries Amendment Act

(111 th Congress) Contact members of House of Representatives Request they co-sponsor HR 653 Contact member of Senate Request they co-sponsor S 305 Work with House and Senate Committees Host briefings Hold meetings

( 111 th Congress) Early January Introduce House and Senate Bills DONE February Meet with NIH/NCI Leadership Hold Congressional briefings Push for passage in sub-committee Meet with sub-committee members and staffers Identify sub-committee champions Push for passage in Committee Meet with sub-committee members and staffers Identify sub-committee champions Push for passage in House and Senate Celebrate

19 Need More Information? Want to Help? Lloyd Morgan, “Chief Cheerleader” ;